• Medhat Askar, Ronald Sobecks, Tao Wang, Mike Haagenson, Navneet Majhail, Abeer Madbouly, Dawn Thomas, Aiwen Zhang, Katharina Fleischhauer, Katharine Hsu, Michael Verneris, Stephanie J Lee, Stephen R Spellman, and Marcelo Fernández-Viña.
• Department of Pathology, Baylor University Medical Center, Dallas, Texas. Electronic address: medhat.askar@baylorhealth.edu.
• Biol. Blood Marrow Transplant. 2017 Mar 1; 23 (3): 436-444.

AbstractSingle-center studies have previously reported associations of MHC Class I Chain-Related Gene A (MICA) polymorphisms and donor-recipient MICA mismatching with graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT). In this study, we investigated the association of MICA polymorphism (MICA-129, MM versus MV versus VV) and MICA mismatches after HCT with 10/10 HLA-matched (n = 552) or 9/10 (n = 161) unrelated donors. Included were adult patients with a first unrelated bone marrow or peripheral blood HCT for acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome that were reported to the Center for International Blood and Marrow Transplant Research between 1999 and 2011. Our results showed that neither MICA mismatch nor MICA-129 polymorphism were associated with any transplantation outcome (P < .01), with the exception of a higher relapse in recipients of MICA-mismatched HLA 10/10 donors (hazard ratio [HR], 1.7; P = .003). There was a suggestion of association between MICA mismatches and a higher risk of acute GVHD grades II to IV (HR, 1.4; P = .013) There were no significant interactions between MICA mismatches and HLA matching (9/10 versus 10/10). In conclusion, the findings in this cohort did not confirm prior studies reporting that MICA polymorphism and MICA mismatches were associated with HCT outcomes.Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…